Prescribing information

 

   

Watch MS experts share their first-hand experience of how their patients have been able to start receiving KESIMPTA and about what treatment is really like for those patients with MS.

 

Where does KESIMPTA fit in clinical practice? Real-world evidence from the National Hospital for Neurology and Neurosurgery (NHNN), London

Watch Consultant Neurologist Dr Wallace Brownlee as he shares his centre’s first experiences of using KESIMPTA for 42 patients. Dr Brownlee then looks in particular detail at three of the cases, and also describes the important decision-making process for those patients at various points in their treatment course.

 

How have patients been initiated onto and responded to KESIMPTA? A nursing perspective and insights so far

Watch Consultant MS Nurse Noreen Baker share how she and her team at NHNN set up the KESIMPTA service, how treatment with KESIMPTA was initiated and received, her experience with using KESIMPTA from a nurse’s point of view, and her key learnings about the service so far.

 
 

KESIMPTA service in Sheffield and South Yorkshire

Watch Consultant Neurologist Dr David Paling share how KESIMPTA is offered from his centre in Sheffield, by utilising telemedicine through KesimptaConnect, in order to maximise access to KESIMPTA for his patients. Dr Paling goes on to describe the safety and tolerability of KESIMPTA for the patients in his care, as compared to that which is published in clinical trials.

 

These meetings were organised and funded by Novartis Pharmaceuticals UK Ltd. The views expressed are those of the speakers and do not necessarily reflect those of Novartis.

MS, multiple sclerosis.

Rate this content: 
No votes yet
UK | May 2022 | 207390
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]